Interferon-alpha in tumor immunity and immunotherapy

Cytokine and Growth Factor Reviews

Volumn 13, Issue 2, 2002, Pages 119-134

  Belardelli, Filippo ^a   Ferrantini, Maria ^a   Proietti, Enrico ^a   Kirkwood, John M ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Immunity; Immunotherapy; Interferon alpha; Tumor

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CANCER VACCINE; GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; QS 21; RECOMBINANT ALPHA2B INTERFERON; SAPONIN DERIVATIVE;

ANIMAL; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL MODEL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA MODIFICATION; DOSE RESPONSE; DRUG EFFICACY; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; MORTALITY; MOUSE; NEOPLASM; NONHUMAN; PHYSIOLOGY; REVIEW; SURVIVAL; T LYMPHOCYTE; TIME; TUMOR CELL; TUMOR IMMUNITY; DISEASE FREE SURVIVAL;

ANIMALS; CANCER VACCINES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MELANOMA; MICE; MODELS, BIOLOGICAL; NEOPLASMS; TIME FACTORS;

EID: 0036005886     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00022-3     Document Type: Review

References (105)

1. Cytokine therapeutics: Lessons from interferon-alpha
2. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons
3. Role of interferons and other cytokines in the regulation of the immune response
4. Type I IFN receptor: Structure, function, and evolution of a family business
5. The neglected role of type I interferon in the T cell response: Implications for its clinical use
6. Gene Therapy of cancer with interferon: Lessons from tumor models and perspectives for clinical applications
7. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
8. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
9. A new American Joint Committee on Cancer staging system for cutaneous melanoma
10. Prognostic factors analysis of 17,600 melanoma patients. Validation of the American joint committee on cancer melanoma staging system
11. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
12. Interferon-alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
13. Pooled-analysis of four ECOG/intergroup trials of high-dose interferon-alpha-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma
14. Randomized, surgical adjuvant clinical trial of recombinant interferon-alpha-2a in selected patients with malignant melanoma
15. High- and low-dose interferon-alpha-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
16. High-dose interferon-alpha-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter ECOG phase II trial: E2696
17. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
18. The orderly progression of melanoma nodal metastases
19. Selective lymphadenectomy: Emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma
20. Evaluation of efficacy of adjuvant rIFN-α2a in melanoma patients with regional node metastases
21. Adjuvant interferon-alpha-2a treatment in resected primary stage II cutaneous melanoma
22. Interferon-alpha and -beta: Clinical applications: Melanoma
23. Induction of TH1 and TH2 responses: A key role for the 'natural' immune response?
24. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
25. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes
26. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
27. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
28. IFN-α-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs
29. Interpheron-alpha (IFN-α) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumor cultures (MLTC)
30. Induction of bystander T cell proliferation by viruses and type I interferon in vivo
31. Type I interferon-mediated stimulation of T cells by CpG DNA
32. Type I interferons keep activated T cells alive
33. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated 1L-2Ralpha, c-myc, and pim-1 genes in human T cells
34. The dendritic cell system and its role in immunogenicity
35. Origin, maturation, and antigen-presenting function of dendritic cells
36. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
37. Type I IFNs enhance the terminal differentiation of dendritic cells
38. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells
39. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-scid mice
40. The nature of the principal type I interferon-producing cells in human blood
41. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon
42. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
43. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells I
44. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms
45. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumor implanted subcutaneously
46. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. IV. Definition of optimal treatment regimens
47. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases
48. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells
49. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases
50. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon-alpha/beta treatment in mice
51. Mechanism of the antitumor effect of interferon in mice
52. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN-α/β therapy of Friend erythroleukemia visceral metastases
53. + T cells and IFN-α/β
54. + T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases
55. + T cells after injection of tumor cells expressing IFN-α into syngeneic mice
56. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stornatitis virus and encephalornyocarditis virus
57. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors
58. Elusive interferon-alpha producers nailed down
59. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice
60. hi T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer
61. Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
62. Cytokines, tumor-cell death, and immunogenicity: A question of choice
63. Cancer vaccines
64. Alpha1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Antitumor therapy by means of interferon-producing cells
65. 1 transfected Friend leukemia cells
66. +T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-γ producing TS/A cells
67. Interferon-beta (IFN-β) gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α. Differential effects on tumorigenicity and host response
68. Interferon-alpha gene therapy for cancer: Retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models
69. 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice
70. Injection of irradiated melanoma genetically modified to secrete IFN-α causes regression of an established tumor
71. 1 gene transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to IFN-α/β therapy
72. The effect of interferon on experimental tumor metastases
73. Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene transduced tumor cells
74. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-alphal and herpes simplex thymidine kinase followed by ganciclovir
75. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVtk: Perspectives for the generation of cancer vaccines
76. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha
77. Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer
78. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon-alpha gene therapy in combination with adoptive chemoimmunotherapy
79. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin
80. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: Implications for new therapeutic strategies with IFN-α
81. IFN-α gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models
82. Nonviral interferon-alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response
83. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon-alpha
84. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells
85. Parameters of interferon action. II. Immunological effects of recombinant leukocyte interferon (IFN-alpha-2) in phase I-II trials
86. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma
87. Increased expression of human monocyte HLA-DR antigen and Fc-gamma receptors in response to human interferon in vivo
88. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon-alpha-2b
89. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon-alpha-2b
90. Interferons in the therapy of solid tumors
91. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response
92. Tumor-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon-alpha treatment
93. Effect of IFN-α on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma
94. + T cells
95. The Philadelphia chromosome translocation: A paradigm for understanding leukemia
96. Chronic myelogenous leukemia: Biology and therapy
97. Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia
98. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T -cells stimulatory activity by IFN-α
99. Interferon-alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia
100. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia
101. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
102. Regulation by interferon α of immunoglobulin isotype selection and lymphokine production in mice
103. Recombinant interferon alpha can induce rearrangement of T-cell antigen receptor alpha-chain genes and maturation to cytotoxicity in T-lymphocyte clones in vitro
104. Functional role of type I and type II interferons in antiviral defense
105. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th-1 type cytokine production and improves the proliferative response to recall antigens